CJC-1295 Dosage: DAC vs No-DAC, Explained
Last updated May 19, 2026 · Reviewed by Grey Peptides Editorial Board · ✓ Primary-sourced
← CJC-1295 encyclopedia entry · See also: Ipamorelin dosage · Sermorelin dosage
CJC-1295 is investigational and was never FDA approved; clinical development was discontinued. There is no label or official dose. Everything below reflects community and compounding practice, documented for education — not instructions for use. Treat the unknowns of any unapproved injectable seriously.
The short version
CJC-1295 is a GHRH analog — but "CJC-1295" actually refers to two different things, and the dosing depends entirely on which one you mean. Getting this distinction right is the whole point of the page, because mixing them up produces order-of-magnitude errors.
CJC-1295 with DAC carries a "drug affinity complex" that binds to albumin in the blood, stretching its half-life to roughly six to eight days. It is therefore dosed in milligram amounts about once or twice weekly.
CJC-1295 without DAC — essentially modified GRF(1-29) — has no albumin anchor and is short-acting, so it is dosed in sub-milligram (microgram) amounts several times daily, much like sermorelin. The two are not interchangeable.
What community protocols report
| Version | Reported amount | Frequency | Route |
|---|---|---|---|
| CJC-1295 with DAC | ~1–2 mg | 1–2× weekly | SubQ |
| CJC-1295 no-DAC (mod GRF 1-29) | ~100 mcg | 1–3× daily | SubQ |
The weekly cadence of the DAC version is the feature that made it popular — far fewer injections than sermorelin-style peptides — but it is also why an error matters more: a single weekly dose sustains drug levels for days. None of these schedules is validated by approval-grade human trials.
The ipamorelin pairing
CJC-1295 is most often combined with ipamorelin: the GHRH analog raises the baseline drive while the GHRP adds a pulse. The pairing is ubiquitous in community protocols, but the combination has not been tested for safety or efficacy at the level a drug approval would require. See the ipamorelin dosage page for the other half.
Reconstitution basics
Both versions are lyophilized powders that require reconstitution with bacteriostatic water. Because the DAC version is dosed in milligrams weekly and the no-DAC version in micrograms daily, using one version's math for the other is a classic and serious mistake. The Reconstitution Calculator converts vial strength and diluent volume into an exact syringe draw, and the Half-Life Visualizer shows how dramatically the DAC and no-DAC half-lives differ. A calculator handles arithmetic but cannot confirm vial contents.
Frequently asked questions
Which version do people usually mean?
Casual references to "CJC-1295" weekly almost always mean the DAC version; "modified GRF(1-29)" or "CJC no-DAC" means the short-acting one. If a source does not specify, the dose it lists is the clue.
Why was development discontinued?
Clinical development did not continue to approval; CJC-1295 remained an investigational compound. As with the other GH secretagogues here, that is why no label exists.
Is the DAC version safer because it's fewer injections?
Fewer injections is a convenience, not a safety guarantee — a long half-life also means a dosing error persists for days, which is its own risk.
Sources
- Teichman SL, et al. "Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295, a long-acting analog of GHRH, in healthy adults." J Clin Endocrinol Metab. 2006;91:799–805.
- Ionescu M, Frohman LA. GHRH-analog pharmacology and pulsatile GH secretion.
Medical disclaimer: Education only, not medical advice. CJC-1295 is investigational and not approved for human use. Dosing figures reflect community/compounding practice, not a recommendation. Do not self-administer; consult a licensed clinician.